Takeda Pharmaceutical Co. (TAK) has received increased attention as it presents itself as a potential value pick due to its positive short-selling prospects. The company saw a strong quarterly growth with a Q1 report surpassing expectations. Furthermore, it plans to increase the dividend to ¥98.00, drawing attention from dividend investors. Despite a 6.19% drop over four weeks, it's thought to be ripe for a turnaround as value investors are encouraged to purchase their shares. Creative Planning has lowered its stake in the company and Millennium Management LLC has secured $56.24 million holdings. It's important to note Takeda is taking some risk with its usage of debt, which could influence your investment decision. The US has allowed for increased production of Takeda's ADHD drug and its generics to address shortages. However, shares slipped after Takeda's announcement regarding a pact for a gastric drug in India. Other developments include the unveiling of an employee incentive plan, a slashed full-year profit forecast due to drug pipeline impairments, a voluntary withdrawal of lung cancer therapy, and the expansion of the pipeline despite growth worries associated with it.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sat, 12 Oct 2024 09:28:38 GMT -
Rating 5
- Innovation -3
- Information 7
- Rumor -2
